^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | Esophageal Adenocarcinoma |
| Drug: | paclitaxel (Bcl2 inhibitor, Tubulin polymerization promoter) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma
Excerpt:
...- Participants must have histologically or pathologically confirmed gastroesophageal adenocarcinoma (stomach, gastroesophageal junction or esophagus) that is unresectable or metastatic and which must be HER2 positive as confirmed by central testing using FDA-approved HER2 assay....
Trial ID:
Source:
Title:
HER2-overexpression/amplification and survival in patients with resectable esophageal/gastroesophageal junction adenocarcinoma (E/GEJ-AC) treated with neoadjuvant carboplatin/paclitaxel-based chemoradiation
Published date:
01/11/2021
Excerpt:
pCR rates were lower in HER2-positive (vs negative) pts (11% [2/19] vs 27% [17/63]). After a median follow up of 23 mo, DFS and TTR were significantly shorter in HER2 positive (vs negative) pts, independent of other pretreatment covariables (Table). Yet OS was comparable. Lung recurrence was enriched in HER2 positive (vs negative) pts. Among pts with recurrence...HER2 positivity (vs negativity) is independently associated with shorter TTR and DFS, but more comparable OS.
